2mg Bortenat Bortezomib Injection

2mg Bortenat Bortezomib Injection Specification

Packaging Type
Vial

Indication
Multiple myeloma, Mantle cell lymphoma

Dosage Form
Injection

Origin of Medicine
India

Salt Composition
Bortezomib 2mg

Life Span
24 months from date of manufacture

Brand Name
Bortenat

Pacakaging (Quantity Per Box)
1 vial per box

Drug Type
Allopathic

Ingredients
Bortezomib

Physical Form
Lyophilized Powder

Function

Recommended For
Patients with multiple myeloma or mantle cell lymphoma

Dosage
As prescribed by the physician, typically 1.3 mg/m2

Dosage Guidelines
To be administered intravenously or subcutaneously under medical supervision

Suitable For
Adults

Storage Instructions
Store below 25C, protect from light

Route of Administration
IV or SC

Prescription Required
Yes

Drug Class
Proteasome Inhibitor

Shelf Life (From Date of Manufacture)
24 months

Color
White to off-white lyophilized powder

Reconstitution
Reconstitute with 2.4 ml 0.9% Sodium Chloride Injection

Molecular Formula
C19H25BN4O4

International Brand Equivalent
Velcade

Marketed By
Natco Pharma Ltd.

2mg Bortenat Bortezomib Injection Trade Information

Minimum Order Quantity
10 Pieces

Supply Ability
1000 Pieces Per Month

Delivery Time
7 Days

About 2mg Bortenat Bortezomib Injection

Strength	2mg
Form	Injection
Manufacturer	Natco
Brand	Bortenat
Packaging Type	Box
Medicine Type	Allopathic
Application	To Treat Multiple Myeloma

Bortenat 2mg & 3.5 mg Injection is used in the treatment of multiple myeloma and mantle-cell lymphoma. It shows its working by stopping or slowing down the growth of cancer cells.

Bortenat 2mg & 3.5 mg Injection is given as an injection by a qualified medical professional. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.

Fatigue, nausea, vomiting, and loss of appetite are some common side effects of this medicine. You may be advised to drink plenty of fluids every day during the treatment. You should not drive or operate machinery as medicine may cause tiredness and dizziness. This medicine may reduce the number of blood cells (decrease red blood and white blood cells) in your blood, thereby, increasing the susceptibility to infections. Regular blood tests are required to check your blood cells along with heart, liver, and blood uric acid levels.

Effective Cancer Treatment for Adults

Bortenat Bortezomib Injection is formulated for adults diagnosed with multiple myeloma and mantle cell lymphoma. As a potent proteasome inhibitor, it interferes with cancer cell growth, making it a vital option in oncology care. Its efficacy aligns with established international standards, providing patients in India with a reliable equivalent to Velcade.

Safe Handling and Administration

This injection is supplied as a lyophilized powder and must be reconstituted with 2.4 ml of 0.9% Sodium Chloride Injection prior to use. Administration is strictly performed by healthcare professionals via intravenous (IV) or subcutaneous (SC) routes. Patients are advised never to self-administer and to always follow their prescribed treatment regimen under medical supervision.

Convenient and Reliable Packaging

Bortenat comes in a single-vial package, ensuring accurate dosing and minimal waste. With a shelf life of 24 months from the manufacturing date, it provides flexibility for both inventory management and patient scheduling. Proper storage below 25C and protection from light preserve its potency throughout its lifespan.

FAQ's of 2mg Bortenat Bortezomib Injection:

Q: How should Bortenat Bortezomib Injection be reconstituted and administered?

A: Bortenat Bortezomib Injection should be reconstituted with 2.4 ml of 0.9% Sodium Chloride Injection. Administration must be carried out by a qualified healthcare professional, using either intravenous (IV) or subcutaneous (SC) routes, as per the physician's instructions.

Q: What conditions is Bortenat Bortezomib Injection recommended for?

A: This injection is primarily indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma. It works by inhibiting proteasomes, thereby disrupting cancer cell growth and survival.

Q: When should the injection be administered, and what is the typical dosage?

A: Bortenat is administered based on a physician's prescription, typically at a dosage of 1.3 mg/m2, according to individual treatment protocols. The exact timing and frequency will be determined by your healthcare provider based on your specific needs and response to therapy.

Q: Where should Bortenat Bortezomib Injection be stored before use?

A: The injection must be stored below 25C and protected from light to maintain its stability and effectiveness. Always keep it in its original packaging until ready to use and out of reach of children.

Q: What are the benefits of using Bortenat Bortezomib Injection in cancer treatment?

A: Bortenat Bortezomib offers a targeted approach for treating multiple myeloma and mantle cell lymphoma. By inhibiting proteasomal activity, it effectively inhibits tumor growth and supports improved patient outcomes as part of chemotherapy regimens.

Q: Is a prescription required to obtain Bortenat Bortezomib Injection?

A: Yes, Bortenat Bortezomib Injection is a prescription-only medication and can only be administered under the supervision of a healthcare professional.

Q: Who manufactures and markets Bortenat Bortezomib Injection?

A: This injection is manufactured and marketed by Natco Pharma Ltd., India, and serves as a locally available equivalent to the international brand Velcade.